PreveCeutical advances drug delivery tech with Sol-Gel platform, eyes multi-asset spinouts

PreveCeutical Medical Chairman Stephen Van Deventer joined Steve Darling from Proactive to discuss the company’s strategic evolution into a multi-asset business and its progress in advancing innovative drug delivery technologies. Van Deventer highlighted that PreveCeutical has spent the past decade developing four research programs, all of which have now reached proof-of-concept. The company is shifting to a model where these assets are spun out as standalone entities, enabling more focused development, specialized funding, and strategic partnerships. A central innovation is the company’s Sol-Gel platform, a nasal drug delivery system designed to improve treatment efficiency. Van Deventer explained, “When it hits the top part of your nasal cavity, it gels instantaneously and it can sit there for up to seven days and time release any type of drugs… bypassing the blood-brain barrier.” This method allows for direct nose-to-brain delivery, potentially lowering dosage requirements and minimizing systemic side effects. PreveCeutical has already spun out BioGene Therapeutics, which is developing RNA-based therapies targeting obesity and diabetes. The company is also advancing a non-addictive pain therapy and exploring additional spinouts, contingent on funding. A recent patent filing for dopamine delivery directly into the brain represents another breakthrough, with potential applications for Parkinson’s disease and broader neurological and psychiatric conditions. Looking ahead, PreveCeutical is preparing to transition from preclinical development to clinical stages, seeking potential partnerships and non-dilutive funding opportunities to accelerate its programs and expand the impact of its technology. #proactiveinvestors #preveceutical #biogenetherapeutics #cse #prev #otcqb #prvcf #DrugDelivery #SolGel #Biotech #Innovation #BrainHealth #Neurology #Pharmaceuticals #RNAtherapy #MedicalInnovation